BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
RIABNI (rituximab-arrx) by Amgen is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2020.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIABNI is a rituximab biosimilar—a CD20-directed monoclonal antibody that depletes B cells in autoimmune and hematologic malignancies. It is approved for 21 indications spanning rheumatoid arthritis, non-Hodgkin lymphoma, chronic lymphocytic leukemia, vasculitis, lupus, and other B-cell-driven diseases. The drug works by binding CD20 antigen on B cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct cell death.
$3MPart D
PeakDrug is in peak commercial phase with modest Part D penetration; Amgen team is likely focused on market expansion across oncology and immunology segments.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on RIABNI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.